Proactive Investors - Run By Investors For Investors

ANGLE hails results from landmark ovarian cancer study which underlines potential of its liquid biopsy

Its Parsortix system was able to detect cancer in 95% of the cases, achieving a lower false positive rate than existing method of detection
ANGLE hails results from landmark ovarian cancer study which underlines potential of its liquid biop
The technology could ultimately help dictate treatment options, streamlining the process

AIM-listed med-tech firm ANGLE plc (LON:AGL,OTCQX:ANPCY) said its ground-breaking liquid biopsy outperformed the current tests used to tell whether a pelvic mass is malignant or benign.

Its Parsortix system was able to detect cancer in 95% of the cases, achieving a lower false positive rate than existing method of detection.

WATCH: ANGLE boss delighted by study results

READ: Our Big Picture overview of the company

ANGLE’s technology was used in harness with a specially-developed algorithm using certain patient data.

Results came from a study of 400 people at two centres – Vienna and New York State.

ANGLE believes the Parsortix blood test has the potential to aid the diagnosis of ovarian cancer before a biopsy or surgery is performed.

Diagnosis before biopsy

Why does this matter? Well, it will allow those with disease to be referred directly to gynaecologic oncology surgeons.

At the same time, it should ensure patients with benign tumours are be cared for in their communities. 

This streamlined strategy has the potential to cut costs and accelerate treatment.

ANGLE’s founder and chief executive said of the latest results: “This success enables ANGLE to move forward into the validation phase for the use of Parsortix in its first clinical application. 

“We believe ANGLE is building momentum towards securing a leading and well differentiated commercial position in the emerging multi-billion dollar liquid biopsy market."

---adds CEO interview---

 

View full AGL profile View Profile

ANGLE PLC Timeline

Related Articles

1550834286_shutterstock_651647128.jpg
February 22 2019
The company is developing drugs for blood disorders, metabolic diseases and curbing alcohol use
consumer health segment overview
January 11 2019
The company sells clinically validated anti-ageing products for hair, skin and body.
pills
January 15 2019
Under former chief executive Peter George and his successor Shaun Chilton, Clinigen has been transformed via a series of well-judged, quickly integrated and cash generative acquisitions

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use